End-stage Heart Failure
Antisense control of phospholamban expression restores cardiac response
Published in Gene Therapy Weekly, April 4th, 2002
Researchers affiliated with the Massachusetts General Hospital and Harvard Medical School in Boston, Massachusetts, have examined whether antisense gene therapy could reverse negative factors influencing human heart failure by studying the myocardial cells of nine patients with end-stage heart failure. They believe that controlling an important protein, phospholamban, may hold the key.
"We tested whether contractile function can be improved by decreasing the inhibitory effects of phospholamban on...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2002-04-04)
More Articles from Gene Therapy Weekly
- Tumor Targeting
T cells used to deliver toxic fusion proteins directly to tumors - Acute Renal Failure
Hepatocyte growth factor DNA stems kidney disease in murine model - Muscular Dystrophy
New gene therapy trials planned - Ocular Inflammation
Topical agent controls herpetic lesions by extinguishing neovascularization - Vascular Gene Delivery
Percutaneous method, smaller volume increase agent retention in heart - Angiogenic Gene Therapy
American Heart Association issues results from Generx trial for stable angina - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
